MOL 4239

Drug Profile

MOL 4239

Alternative Names: MOL4239; WP 1220

Latest Information Update: 29 Jul 2016

Price : $50

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Dermin; Moleculin; Moleculin Biotech
  • Class Antipsoriatics; Cinnamates; Small molecules
  • Mechanism of Action STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cutaneous T cell lymphoma
  • Discontinued Plaque psoriasis

Most Recent Events

  • 01 Feb 2016 Discontinued - Phase-II for Plaque psoriasis in USA (Topical)
  • 01 Feb 2016 Moleculin and Dermin plan a clinical trial for Cutaneous T-cell lymphoma (Early-stage disease) in Poland (Moleculin Form S-1, February 2016)
  • 01 Aug 2013 Moleculin completes a phase IIa trial in mild-to-moderate Plaque psoriasis in USA (NCT01826201)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top